Dianthus Therapeutics Inc (DNTH) financials
Dianthus Therapeutics revenue and earnings by year
Dianthus Therapeutics's revenue was $2.04 million in the fiscal year to December 31, 2025, down 67.3% from the year before. Net income was -$162 million, -7973.3% of revenue. Since the fiscal year to December 31, 2022, revenue has shrunk 31.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 4 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 2 | 6 | 3 | 6 |
| Revenue growth | -67.3% | 120.6% | -56.0% | — |
| Operating income | -178 | -102 | -48 | -30 |
| Operating margin | -8739.3% | -1633.7% | -1704.7% | -462.9% |
| Net income | -162 | -85 | -44 | -28 |
| Net margin | -7973.3% | -1362.8% | -1541.2% | -443.8% |
| Diluted EPS | -$4.20 | -$2.55 | -$8.45 | -$32.57 |
| Free cash flow | -129 | -78 | -37 | -29 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open DNTH in Markets.
See also: DNTH returns
No forecast, no recommendation. This page describes Dianthus Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.